Investors

Histogen, a regenerative medicine company with a hair growth product in US human clinical trials, has recently closed a skin care partnership with Allergan for the dermatology market and is actively seeking to partner in the retail skin care market.  The Company’s patented technology focuses on stimulating a patient’s own stem cells to regenerate tissues. Histogen’s core technology yields a set of individual products that have been shown to support stem cell growth and differentiation, and thus regeneration, in several human tissues. Its lead therapeutic product stimulates hair growth, addressing a multibillion dollar global market.  Other applications of Histogen’s technology include skincare, orthopedics indications such as cartilage formation and spinal disk repair, wound healing and dermal fillers.

Histogen has raised $38M in equity, the majority of which has been used to develop and optimize its proprietary manufacturing process, submit patents in a number of countries, and refine and advance its products. The Company intends to build on previous clinical experience through completion of initial North American clinical trials of its hair growth product in 2018 and 2019.

For more information about investment opportunities please contact:

Eileen Brandt
Director of Corporate Communications
858.526.3100

ebrandt@histogeninc.com

investor

Market Highlights:

Hair loss affects an estimated 50 million men and 30 million women in the United States alone.

The global cosmeceutical market is projected to reach $61 billion by 2020, representing the fastest growing segment in the cosmetic industry.

Aesthetic injectables have proven immensely popular with patients and dermatologists alike.